Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Dry Eye · Conjunctivitis, Allergic · ALDX

Aldeyra Therapeutics

Aldeyra Therapeutics patent portfolio — 38 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US HQ
2004 Founded
14 Employees
Public company Type
ALDX · NYSE Ticker
Company details
Status
Public
HQ
131 Hartwell Avenue, Suite 320, Lexington, Massachusetts 02421, US
Founded
2004
Employees
14
Programs
26
Drugs
12
Patents
38
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Aldeyra Therapeutics patents

38 pharmaceutical patents indexed for Aldeyra Therapeutics. 0 expire within 24 months.

Aldeyra Therapeutics has 38 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

38 patents

Patent portfolio

  1. US 12240816

    Deuterated compounds and uses thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12128013

    Toxic aldehyde related diseases and treatment

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12097188

    Compositions and methods for the treatment of macular degeneration

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12064516

    Pharmaceutical formulations and uses thereof

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12029735

    Polymorphic compounds and uses thereof

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12005061

    Ophthalmic formulations of methotrexate

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12005060

    Ophthalmic formulations of methotrexate

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12006298

    Polymorphic compounds and uses thereof

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11911385

    Methotrexate treatment methods

    Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11845722

    Deuterated compounds and uses thereof

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11786518

    Ophthalmic formulations and uses thereof

    Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11771664

    Toxic aldehyde related diseases and treatment

    Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11724987

    Compositions and methods of treating retinal disease

    Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11701331

    Toxic aldehyde related diseases and treatment

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11583529

    Treatment of inflammatory disorders

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11459300

    Deuterated compounds and uses thereof

    Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11312692

    Polymorphic compounds and uses thereof

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11197821

    Formulations for treatment of dry eye disease

    Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11129823

    Combination treatment of ocular inflammatory disorders and diseases

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11046650

    Deuterated compounds and uses thereof

    Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11040039

    Treatment of inflammatory disorders

    Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11007157

    Toxic aldehyde related diseases and treatment

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10913722

    Compositions and methods of treating retinal disease

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10588874

    Toxic aldehyde related diseases and treatment

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10550085

    Deuterated compounds and uses thereof

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10543181

    Toxic aldehyde related diseases and treatment

    Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10426790

    Treatment of allergic eye conditions with cyclodextrins

    Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10414732

    Polymorphic compounds and uses thereof

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10213395

    Toxic aldehyde related diseases and treatment

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10202348

    Compositions and methods of treating retinal disease

    Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10111862

    Traps in the treatment of macular degeneration

    Expires Mon Oct 25 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9896419

    Compositions and methods of treating retinal disease

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9814701

    Compositions and methods for the treatment of macular degeneration

    Expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9687481

    Toxic aldehyde related diseases and treatment

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9650342

    Compositions and methods of treating retinal disease

    Expires Mon May 11 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9604997

    Peri-carbinols

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9364471

    Compositions and methods of treating retinal disease

    Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9265759

    Compositions and methods of treating retinal disease

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Aldeyra Therapeutics have?

38 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Aldeyra Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.